ADARx Pharmaceuticals, Inc.

Nasdaq: ADRX

Day 12 public/RECENT/IPO Sep 28, 2026/Pharmaceutical Preparations

$17.78

▲ 0.10 (+0.59%)

LIVE

updated 14h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionMarket Positioning · Day 8–30

Understand early market positioning and the first institutional moves.

Focus

Institutional activityPrice behaviorVolumeCatalystsFirst major events

NEUTRALFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence45%

CURRENT THESIS INTERPRETED

ADARx Pharmaceuticals, Inc. is a newly public clinical-stage pharmaceutical company with no reported XBRL fundamentals or 10-Q/10-K filings yet. Institutional engagement is evidenced by multiple Schedule 13D and 13G filings, alongside active insider transactions.

Momentum

Price · since IPOLIVE

Yahoo · 11 pts

H $20.64L $17.33Last $17.78

Current ThesisINTERPRETEDLIVE

Why

+High institutional interest with 3 Schedule 13D/13G filings on record
+Active insider reporting with 24 insider forms filed with the SEC
+Stable near-term price momentum trading at $17.78

Risks

−Absence of historical XBRL fundamentals and 10-Q/10-K filings
−High risk score due to newly public status of under 90 days in the clinical-stage sector

Catalysts

→Upcoming financial disclosures and first periodic reports (10-Q/10-K)
→Future clinical-stage pipeline updates and disclosures

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://adarx.com

VIEW-ONLY

Visit

LIVE · SANDBOXED · source: SEC 424B4

Resolving official website…

Research EnvironmentLIVE

Research environment · $ADRXSEC · market · news

15 evidence items|newest evidence 4d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 65/100 recomputed from 4 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Market Positioning.via Intelligence Core

14h agoOBSERVATIONVERIFIEDLast price $17.78 · +0.59% on the day.via Finnhub quoteVERIFIED

4d agoEVIDENCEPrimary Markets Group September 2026 U.S. IPO Updatevia SeekingAlpha · tier 3, cross-check Oct 5, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D filed.via SEC EDGARVERIFIED Oct 2, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D filed.via SEC EDGARVERIFIED 8d agoEVIDENCEADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offeringvia Yahoo · tier 3, cross-check Oct 1, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED Sep 30, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED Sep 30, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED 12d agoEVIDENCEADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?via Yahoo · tier 3, cross-check

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-10-05	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	SEC ↗
2026-10-02	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	SEC ↗
2026-10-01	SCHEDULE 13G	ADARx Pharmaceuticals, Inc.	SEC ↗
2026-09-30	4	ADARx Pharmaceuticals, Inc.	SEC ↗
2026-09-30	4

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics